| Jeffrey Jason White, MD | |
|
2170 Midland Rd, Southern Pines, NC 28387-2927 | |
| (910) 295-2100 | |
| (910) 295-3625 |
| Full Name | Jeffrey Jason White |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 24 Years |
| Location | 2170 Midland Rd, Southern Pines, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245221563 | NPI | - | NPPES |
| 313921 | Other | NC | WELLPATH |
| FH2967125 | Other | NC | FIRSTCAROLINACARE |
| E3504 | Other | NC | MEDCOST |
| P00267355 | Other | NC | RAILROAD MEDICARE |
| N01639 | Medicaid | SC | |
| 1363T | Other | NC | BCBS |
| 27754 | Other | NC | OPTICARE |
| 891363T | Medicaid | NC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207WX0200X | Ophthalmology - Ophthalmic Plastic And Reconstructive Surgery | 200201639 (North Carolina) | Secondary |
| 207W00000X | Ophthalmology | 200201639 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Firsthealth Moore Regional Hospital | Pinehurst, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Carolina Eye Associates Inc | 0446245864 | 35 |
News Archive
Women with a certain type of breast cancer have been given hope in the form of a vaccine which promises to eliminate the cancer tumours.
A major new finding that will significantly advance efforts to create the world's first antibody-based AIDS vaccine was published today by researchers from the La Jolla Institute for Allergy and Immunology.
The University of Missouri Friday announced the discovery of a process to minimize the side effect of painful arthritis that develop after knee surgeries. The procedure will be tested in human clinical trials this summer if the process is approved by the Food and Drug Administration, the Columbia, Mo-based school said.
No one knows for sure how they got there. But the discovery that bacteria that normally live in the gut can be detected in the lungs of critically ill people and animals could mean a lot for intensive care patients.
YM BioSciences Inc., is presenting posters on its JAK1/2 inhibiting small molecule (CYT387) and on its novel vascular disrupting agent (CYT997) at the Lorne Cancer Conference in Lorne, Victoria, Australia. CYT387 is an oral JAK1/2 inhibitor, originating from the seminal discovery of JAK1 and JAK2 kinases by Dr. Andrew Wilks, the founder of Cytopia Limited, now YM Australia. CYT997 is an orally-available agent with dual mechanisms of vascular disruption and cytotoxicity and has the potential to be broadly active against a range of tumor types.
› Verified 1 days ago
| Entity Name | Carolina Eye Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649349291 PECOS PAC ID: 0446245864 Enrollment ID: O20040415001335 |
News Archive
Women with a certain type of breast cancer have been given hope in the form of a vaccine which promises to eliminate the cancer tumours.
A major new finding that will significantly advance efforts to create the world's first antibody-based AIDS vaccine was published today by researchers from the La Jolla Institute for Allergy and Immunology.
The University of Missouri Friday announced the discovery of a process to minimize the side effect of painful arthritis that develop after knee surgeries. The procedure will be tested in human clinical trials this summer if the process is approved by the Food and Drug Administration, the Columbia, Mo-based school said.
No one knows for sure how they got there. But the discovery that bacteria that normally live in the gut can be detected in the lungs of critically ill people and animals could mean a lot for intensive care patients.
YM BioSciences Inc., is presenting posters on its JAK1/2 inhibiting small molecule (CYT387) and on its novel vascular disrupting agent (CYT997) at the Lorne Cancer Conference in Lorne, Victoria, Australia. CYT387 is an oral JAK1/2 inhibitor, originating from the seminal discovery of JAK1 and JAK2 kinases by Dr. Andrew Wilks, the founder of Cytopia Limited, now YM Australia. CYT997 is an orally-available agent with dual mechanisms of vascular disruption and cytotoxicity and has the potential to be broadly active against a range of tumor types.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jeffrey Jason White, MD 2170 Midland Rd, Southern Pines, NC 28387-2927 Ph: (910) 295-2100 | Jeffrey Jason White, MD 2170 Midland Rd, Southern Pines, NC 28387-2927 Ph: (910) 295-2100 |
News Archive
Women with a certain type of breast cancer have been given hope in the form of a vaccine which promises to eliminate the cancer tumours.
A major new finding that will significantly advance efforts to create the world's first antibody-based AIDS vaccine was published today by researchers from the La Jolla Institute for Allergy and Immunology.
The University of Missouri Friday announced the discovery of a process to minimize the side effect of painful arthritis that develop after knee surgeries. The procedure will be tested in human clinical trials this summer if the process is approved by the Food and Drug Administration, the Columbia, Mo-based school said.
No one knows for sure how they got there. But the discovery that bacteria that normally live in the gut can be detected in the lungs of critically ill people and animals could mean a lot for intensive care patients.
YM BioSciences Inc., is presenting posters on its JAK1/2 inhibiting small molecule (CYT387) and on its novel vascular disrupting agent (CYT997) at the Lorne Cancer Conference in Lorne, Victoria, Australia. CYT387 is an oral JAK1/2 inhibitor, originating from the seminal discovery of JAK1 and JAK2 kinases by Dr. Andrew Wilks, the founder of Cytopia Limited, now YM Australia. CYT997 is an orally-available agent with dual mechanisms of vascular disruption and cytotoxicity and has the potential to be broadly active against a range of tumor types.
› Verified 1 days ago
Dr. Tarra Wright Millender, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2170 Midland Rd, Southern Pines, NC 28387 Phone: 910-295-2100 Fax: 910-295-5339 | |
Winston Joseph Garris, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2170 Midland Rd, Southern Pines, NC 28387 Phone: 910-295-2100 Fax: 910-295-0917 | |
Dr. John Wesley French, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2170 Midland Rd, Southern Pines, NC 28387 Phone: 910-295-2100 Fax: 910-295-3625 | |
Dr. Daniel Kent Messner, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2170 Midland Rd, Southern Pines, NC 28387 Phone: 910-295-2100 Fax: 910-295-3625 | |
Robert Allan Sharpe, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2170 Midland Rd, Southern Pines, NC 28387 Phone: 910-295-2100 Fax: 910-295-3625 | |
Dr. Gregory Julian Mincey, MD Ophthalmology Medicare: Medicare Enrolled Practice Location: 2170 Midland Rd, Southern Pines, NC 28387 Phone: 910-295-2100 Fax: 910-295-3625 |